Oral small-molecule therapies are redefining first-line treatment in moderate to severe ulcerative colitis (UC) by offering noninfusion alternatives with rapid onset and high efficacy. Etrasimod, a ...
Credit: Getty Images. Velsipity is a sphingosine 1-phosphate (S1P) receptor modulator. The Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod) for the treatment of moderately to ...
ORLANDO -- For patients diagnosed with moderate to severe ulcerative colitis, the investigational agent icanbelimod had mixed results in reducing the severity of disease within 12 weeks when used as ...
Johnson & Johnson (NYSE:JNJ) said on Monday that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative colitis, met the main goal. JNJ stock up about 1% in ...
The FDA approved oral etrasimod (Velsipity) on Friday for treating moderately to severely active ulcerative colitis (UC) in adults, drugmaker Pfizer announced. Approval of the selective ...
Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated ...
Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company will present its abstract evaluating the impact of ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor ...
AbbVie aims to advance the clinical development of NX-13 as an oral asset for ulcerative colitis and Crohn's disease. September’s volatility catalysts are coming. Find out how to trade new inflation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results